$OPK
OPKO HEALTH, INC. Stock $opk

$opk Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000094480921000027 Filed on April 28, 2021

Income Statement

Concept	2021 Q1	2020 Q4	2020 Q1
Revenue	$545.2M	$494.7M	$211.5M
YoY Change	157.8%	120.5%	-4.94%
Cost Of Revenue	$363.5M	$318.7M	$140.3M
YoY Change	159.09%	123.96%	-2.64%
Gross Profit	$181.7M	$175.9M	$71.20M
YoY Change	155.2%	114.25%	-9.18%
Gross Profit Margin	33.33%	35.56%	33.67%
Selling, General & Admin	$112.3M	$101.8M	$76.13M
YoY Change	47.49%	28.7%	-19.99%
% of Gross Profit	61.8%	57.87%	106.93%
Research & Development	$19.32M	$17.50M	$21.76M
YoY Change	-11.24%	-23.91%	-40.43%
% of Gross Profit	10.63%	9.95%	30.56%
Depreciation & Amortization	$19.99M	$20.10M	$22.05M
YoY Change	-9.36%	-10.67%	-7.41%
% of Gross Profit	11.0%	11.43%	30.97%
Operating Expenses	$506.7M	$445.3M	$252.2M
YoY Change	100.9%	32.22%	-15.29%
Operating Profit	$38.44M	-$269.4M	-$40.76M
YoY Change	-194.3%	5.78%	-45.88%
Interest Expense	-$5.800M	-$5.500M	-$4.700M
YoY Change	23.4%	7.84%	23.68%
% of Operating Profit	-15.09%
Other Income/Expense, Net	-$6.756M	$2.100M	-$17.07M
YoY Change	-60.41%	-76.92%	507.94%
Pretax Income	$31.68M	$45.90M	-$57.83M
YoY Change	-154.79%	-142.34%	-25.98%
Income Tax	$560.0K	$13.60M	$1.171M
% Of Pretax Income	1.77%	29.63%
Net Earnings	$31.08M	$32.30M	-$59.13M
YoY Change	-152.56%	-128.75%	-26.78%
Net Earnings / Revenue	5.7%	6.53%	-27.96%
Basic Earnings Per Share	$0.05	$0.05	-$0.09
Diluted Earnings Per Share	$0.05	$0.05	-$0.09
COMMON SHARES
Basic Shares Outstanding	640.9M shares	670.0M shares	669.8M shares
Diluted Shares Outstanding	640.9M shares

Balance Sheet

Concept	2021 Q1	2020 Q4	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$89.50M	$72.20M	$34.50M
YoY Change	159.42%	-15.56%	-83.36%
Cash & Equivalents	$89.50M	$72.21M	$34.53M
Short-Term Investments
Other Short-Term Assets	$5.063M	$5.309M	$15.79M
YoY Change	-67.93%	-66.48%	249.94%
Inventory	$159.1M	$132.3M	$58.70M
Prepaid Expenses
Receivables	$320.5M	$286.3M	$132.5M
Other Receivables	$9.800M	$16.00M	$14.20M
Total Short-Term Assets	$599.0M	$523.2M	$274.5M
YoY Change	118.27%	61.45%	-36.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$139.1M	$140.6M	$127.3M
YoY Change	9.24%	10.58%	-9.05%
Goodwill	$718.6M	$680.6M	$710.0M
YoY Change	1.22%	1.29%	-0.28%
Intangibles
YoY Change
Long-Term Investments	$10.40M	$15.70M	$10.60M
YoY Change	-1.89%	-23.79%	-66.24%
Other Assets	$9.745M	$10.06M	$7.026M
YoY Change	38.7%	46.05%	124.76%
Total Long-Term Assets	$1.921B	$1.950B	$1.958B
YoY Change	-1.92%	-1.78%	-8.5%
TOTAL ASSETS
Total Short-Term Assets	$599.0M	$523.2M	$274.5M
Total Long-Term Assets	$1.921B	$1.950B	$1.958B
Total Assets	$2.520B	$2.473B	$2.233B
YoY Change	12.86%	7.09%	-13.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$162.7M	$100.9M	$55.87M
YoY Change	191.21%	61.32%	9.36%
Accrued Expenses	$213.1M	$240.9M	$164.9M
YoY Change	29.21%	46.05%	-24.18%
Deferred Revenue	$15.03M	$15.78M	$10.46M
YoY Change	43.77%	-17.78%	-83.99%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$20.10M	$27.20M	$15.40M
YoY Change	30.52%	119.35%	-86.66%
Total Short-Term Liabilities	$403.9M	$375.5M	$245.1M
YoY Change	64.81%	50.72%	-38.12%
LONG-TERM LIABILITIES
Long-Term Debt	$3.325M	$3.837M	$3.538M
YoY Change	-6.02%	-1.77%	-18.14%
Other Long-Term Liabilities	$26.71M	$37.07M	$77.76M
YoY Change	-65.65%	-57.78%	-0.52%
Total Long-Term Liabilities	$419.1M	$426.0M	$438.8M
YoY Change	-4.49%	-4.35%	5.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$403.9M	$375.5M	$245.1M
Total Long-Term Liabilities	$419.1M	$426.0M	$438.8M
Total Liabilities	$823.1M	$801.5M	$683.9M
YoY Change	20.34%	15.41%	-15.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.451B	-$1.482B	-$1.572B
YoY Change	-7.69%	-1.94%	23.07%
Common Stock	$6.707M	$6.706M	$6.704M
YoY Change	0.04%	0.03%	8.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.791M	$1.791M	$1.791M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	549.9K shares	549.9K shares	549.9K shares
Shareholders Equity	$1.697B	$1.672B	$1.549B
YoY Change
Total Liabilities & Shareholders Equity	$2.520B	$2.473B	$2.233B
YoY Change	12.86%	7.09%	-13.31%

Cashflow Statement

Concept	2021 Q1	2020 Q4	2020 Q1
OPERATING ACTIVITIES
Net Income	$31.08M	$32.30M	-$59.13M
YoY Change	-152.56%	-128.75%	-26.78%
Depreciation, Depletion And Amortization	$19.99M	$20.10M	$22.05M
YoY Change	-9.36%	-10.67%	-7.41%
Cash From Operating Activities	$26.04M	$34.30M	-$43.37M
YoY Change	-160.03%	-174.57%	-11.47%
INVESTING ACTIVITIES
Capital Expenditures	-$9.200M	-$6.800M	-$5.600M
YoY Change	64.29%	78.95%	93.1%
Acquisitions
YoY Change
Other Investing Activities	$8.100M	$100.0K	$0.00
YoY Change		0.0%	-100.0%
Cash From Investing Activities	-$1.106M	-$6.700M	-$5.619M
YoY Change	-80.32%	76.32%	35.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$7.192M	8.100M	-$1.611M
YoY Change	346.43%	-88.53%	-100.98%
NET CHANGE
Cash From Operating Activities	$26.04M	34.30M	-$43.37M
Cash From Investing Activities	-$1.106M	-6.700M	-$5.619M
Cash From Financing Activities	-$7.192M	8.100M	-$1.611M
Net Change In Cash	$17.29M	35.70M	-$50.92M
YoY Change	-133.96%	71.63%	-145.97%
FREE CASH FLOW
Cash From Operating Activities	$26.04M	$34.30M	-$43.37M
Capital Expenditures	-$9.200M	-$6.800M	-$5.600M
Free Cash Flow	$35.24M	$41.10M	-$37.77M
YoY Change	-193.29%	-197.39%	-18.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000944809
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201807Member
CY2018Q3	opk	Number Of Derivative Lawsuits NumberOfDerivativeLawsuits	12	lawsuit
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:PropertyPlantAndEquipmentNet
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-33528
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	OPKO Health, Inc.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-2402409
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4400 Biscayne Blvd.
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33137
CY2021Q1	dei	City Area Code CityAreaCode	(305)
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	575-4100
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2021Q1	dei	Trading Symbol TradingSymbol	OPK
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	670153274	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89503000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72211000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	320462000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	286314000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	159104000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	132341000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	29980000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32313000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	599049000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	523179000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	139069000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	140554000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	456309000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	475002000	USD
CY2021Q1	opk	In Process Researchand Development InProcessResearchandDevelopment	590200000	USD
CY2020Q4	opk	In Process Researchand Development InProcessResearchandDevelopment	590200000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	676162000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	680602000	USD
CY2021Q1	us-gaap	Long Term Investments LongTermInvestments	10410000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	15731000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38631000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	37735000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9745000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10060000	USD
CY2021Q1	us-gaap	Assets Assets	2519575000	USD
CY2020Q4	us-gaap	Assets Assets	2473063000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	162690000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	100883000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	213119000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	240869000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10305000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9028000	USD
CY2021Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	17816000	USD
CY2020Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	24703000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	403930000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	375483000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32394000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29760000	USD
CY2021Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	224782000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	221989000	USD
CY2021Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	135244000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	137208000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	26711000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37072000	USD
CY2021Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	419131000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	426029000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	823061000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	801512000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	670703076	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	670585576	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	6707000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	6706000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	549907	shares
CY2021Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	549907	shares
CY2021Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1791000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1791000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3155648000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3152694000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13295000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4225000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1450755000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1481833000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1696514000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1671551000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2519575000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2473063000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	545165000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	211466000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	112286000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	76132000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19315000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21760000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-957000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-860000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12577000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14938000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	506728000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	252228000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	38437000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-40762000	USD
CY2021Q1	opk	Interest Income Nonoperating InterestIncomeNonoperating	5000	USD
CY2020Q1	opk	Interest Income Nonoperating InterestIncomeNonoperating	142000	USD
CY2021Q1	opk	Interest Expense Nonoperating InterestExpenseNonoperating	5395000	USD
CY2020Q1	opk	Interest Expense Nonoperating InterestExpenseNonoperating	5496000	USD
CY2021Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-439000	USD
CY2020Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	621000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-927000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12332000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6756000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17065000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	31681000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-57827000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	560000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1171000	USD
CY2021Q1	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	31121000	USD
CY2020Q1	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	-58998000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-43000	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-134000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	31078000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-59132000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.05
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	640853200	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	640578794	shares
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	31078000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-59132000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9070000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-8117000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	22008000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-67249000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1671551000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2647000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	308000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	31078000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9070000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1696514000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1614759000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2451000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-59132000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8117000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1548619000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	31078000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-59132000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19989000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22052000	USD
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	2585000	USD
CY2020Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	2483000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	222000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	203000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-43000	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-134000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2647000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2451000	USD
CY2021Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	3039000	USD
CY2020Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-102000	USD
CY2021Q1	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	279000	USD
CY2020Q1	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	-9259000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-957000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-860000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1033000	USD
CY2020Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	613000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35238000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	763000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	27912000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8831000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1415000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	729000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1255000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-60000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	62231000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4865000	USD
CY2021Q1	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	946000	USD
CY2020Q1	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	56000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-790000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-9451000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-27126000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3848000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	26037000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43370000	USD
CY2021Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	8079000	USD
CY2020Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	60000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7000	USD
CY2021Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	9245000	USD
CY2020Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5626000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1106000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5619000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	308000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2021Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	472213000	USD
CY2020Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	186398000	USD
CY2021Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	479713000	USD
CY2020Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	188009000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7192000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1611000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-447000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-322000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17292000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50922000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72211000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85452000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89503000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34530000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	4689000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	5012000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1470000	USD
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	799000	USD
CY2021Q1	opk	Numberof Sales Employees NumberofSalesEmployees	300	employee
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.</span>
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	3100000	USD
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	600000	USD
CY2021Q1	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1700000000	USD
CY2020Q4	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1700000000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	676200000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	680600000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1000000000.0	USD
CY2021Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1000000000.0	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12600000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14900000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	7400000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	7100000	USD
CY2021Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of credit risk and allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span>While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2500000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2100000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	300000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2600000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2500000	USD
CY2021Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	117500	shares
CY2021Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	117500	shares
CY2021Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	117500	shares
CY2021Q1	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
CY2021Q1	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
CY2020Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	0	shares
CY2020Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	0	shares
CY2021Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	322940000	USD
CY2020Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	288369000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2478000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2055000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	320462000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	286314000	USD
CY2021Q1	us-gaap	Other Inventory Supplies OtherInventorySupplies	114042000	USD
CY2020Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	86779000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	39287000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	36831000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	4706000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5268000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5966000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5784000	USD
CY2021Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4897000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2321000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	159104000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	132341000	USD
CY2021Q1	opk	Taxes Recoverable Current TaxesRecoverableCurrent	9480000	USD
CY2020Q4	opk	Taxes Recoverable Current TaxesRecoverableCurrent	13440000	USD
CY2021Q1	us-gaap	Supplies Supplies	13628000	USD
CY2020Q4	us-gaap	Supplies Supplies	7259000	USD
CY2021Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1458000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3803000	USD
CY2021Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	351000	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2502000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	5063000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5309000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	29980000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32313000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	365074000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	356830000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	456309000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	475002000	USD
CY2021Q1	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	50732000	USD
CY2020Q4	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	72160000	USD
CY2021Q1	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	17777000	USD
CY2020Q4	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	15454000	USD
CY2021Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	46428000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	43300000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15031000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15783000	USD
CY2021Q1	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	6597000	USD
CY2020Q4	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	7112000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1188000	USD
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2287000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2453000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4790000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4985000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	69477000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	78434000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	213119000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	240869000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	246517000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	251205000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	246517000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	251205000	USD
CY2021Q1	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	11	institution
CY2020Q4	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	11	institution
CY2021Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	105795000	USD
CY2021Q1	us-gaap	Line Of Credit LineOfCredit	16093000	USD
CY2020Q4	us-gaap	Line Of Credit LineOfCredit	22954000	USD
CY2021Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-4440000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	676162000	USD
CY2021Q1	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	385000	USD
CY2021Q1	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	2479000	USD
CY2020Q4	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	426000	USD
CY2020Q4	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	2252000	USD
CY2021Q1	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	1057000	USD
CY2021Q1	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	12000	USD
CY2020Q4	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	1060000	USD
CY2020Q4	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	9000	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	8837000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	14136000	USD
CY2021Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	35000	USD
CY2020Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	35000	USD
CY2021Q1	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	96000	USD
CY2020Q4	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	74000	USD
CY2021Q1	us-gaap	Long Term Investments LongTermInvestments	10410000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	15731000	USD
CY2021Q1	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	7600000	USD
CY2021Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	2780000	USD
CY2020Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-9880000	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	2981000	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-201000	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-9880000	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	8837000	USD
CY2021Q1	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	96000	USD
CY2021Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	8933000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3564000	USD
CY2021Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3770000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	14136000	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	74000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3564000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4507000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3325000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3837000	USD
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2506000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2805000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	557000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	595000	USD
CY2021Q1	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	16759000	USD
CY2020Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	25328000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	26711000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37072000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	718625000	USD
CY2021Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	38023000	USD
CY2021Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	14210000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	5695000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6735000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3600000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	5700000	USD
CY2021Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	USD
CY2020Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	94000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3600000	USD
CY2018Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	100000	USD
CY2021Q1	opk	Number Of Class Action Lawsuits NumberOfClassActionLawsuits	2	lawsuit
CY2021Q1	us-gaap	Purchase Obligation PurchaseObligation	301500000	USD
CY2021Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	28000000.0	USD
CY2020Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	8900000	USD
CY2021Q1	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	11800000	USD
CY2020Q4	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	14900000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16378000	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15588000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	790000	USD
CY2017Q4	opk	Proceeds From Development And License Agreement Upfront Payment ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment	6000000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	USD
CY2021Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	38437000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-40762000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19989000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22052000	USD
CY2021Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-43000	USD
CY2020Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-134000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	545165000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	211466000	USD
CY2021Q1	us-gaap	Assets Assets	2519575000	USD
CY2020Q4	us-gaap	Assets Assets	2473063000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	676162000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	680602000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38631000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	800000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	37735000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	4793000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	5258000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10305000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9028000	USD
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2287000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2453000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32394000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29760000	USD
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2506000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2805000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M24D
CY2021Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.057
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2021Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.043
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.036
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	7492000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	1869000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10666000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1525000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7471000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	921000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5587000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	571000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3714000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	113000	USD
CY2021Q1	opk	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	16364000	USD
CY2021Q1	opk	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	0	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	51294000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	4999000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8595000	USD
CY2021Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	206000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	42699000	USD
CY2021Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	4793000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4500000	USD
CY2021Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	600000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	700000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4600000	USD
CY2020Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	700000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4245000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4698000	USD
CY2021Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	33000	USD
CY2020Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	45000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	525000	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	493000	USD
CY2021Q1	opk	Payments For Leases PaymentsForLeases	4803000	USD
CY2020Q1	opk	Payments For Leases PaymentsForLeases	5236000	USD

Files In Submission

Name	View Source	Status
0000944809-21-000027-index-headers.html	Edgar Link	pending
0000944809-21-000027-index.html	Edgar Link	pending
0000944809-21-000027.txt	Edgar Link	pending
0000944809-21-000027-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opk-20210331.htm	Edgar Link	pending
opk-20210331.xsd	Edgar Link	pending
opk-20210331_cal.xml	Edgar Link	unprocessable
opk-20210331_def.xml	Edgar Link	unprocessable
opk-20210331_htm.xml	Edgar Link	completed
opk-20210331_lab.xml	Edgar Link	unprocessable
opk-20210331_pre.xml	Edgar Link	unprocessable
opk-3312021xex311.htm	Edgar Link	pending
opk-3312021xex312.htm	Edgar Link	pending
opk-3312021xex321.htm	Edgar Link	pending
opk-3312021xex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPK
OPKO HEALTH, INC. Stock $opk

2021 Q1 Form 10-Q Financial Statement

#000094480921000027 Filed on April 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK OPKO HEALTH, INC. Stock $opk

2021 Q1 Form 10-Q Financial Statement

#000094480921000027 Filed on April 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK
OPKO HEALTH, INC. Stock $opk